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Introduction
The role of methicillin resistant Staphylococcus
aureus (MRSA) as being a major cause of nosocomial as well
as community acquired infections is already known. It has
been recognized that nasal colonization is a vital step in the
pathogenesis of MRSA infections. In addition to self
infection, colonized individuals are a potential MRSA
reservoir for its spread. Hence, eradicating or suppressing
MRSA colonization has remained a cost effective strategy for
preventing infections and transmission.1
Mupirocin (pseuodmonic acid A) is a topical
antimicrobial agent with excellent antistaphylococcal and
antistreptococcal activity. It has already been recognized as
the best and most effective topical antimicrobial agent for
decolonization.2-4 A nasal formulation is approved by the
United States Food and Drug Administration for eradicating
nasal carriage in adult patients as well as in health care
personnel. Moreover topical application of mupirocin has
also been proved to be effective in eradicating MRSA in cases
of impetigo and burn wound infections, as per the
recommendations by the IDSA Practice Guidelines for the
Management of Skin and Soft-Tissue Infections.5
Studies describe two types of phenotypic resistance to
mupirocin, low and high level, with MICs in the range of 8-
256 µg/ml and > 512µg/ml respectively. Detection and
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Abstract
Objective: To evaluate the trend of mupirocin resistance in MRSA, isolated at the Clinical Microbiology
Laboratory of a tertiary care hospital.
Methods: A total of 200 MRSA strains recovered over a 2 year period from various body sites were tested using
the 5 and 200µg discs of mupirocin to detect its resistance. 
Results: High level and low level mupirocin resistance were detected in zero and 1 % of MRSA strains,
respectively. Resistance to other non ß lactam antibiotics was also high. No MRSA strains were found to be
resistant to vancomycin and tegicycline. 
Conclusion: Mupirocin resistance was found to be very low among local clinical isolates of MRSA. Its judicious
use to decolonize nasal carriers should be promoted among hospitalized patients to avoid further transmission
and infections due to prevalent endemic MRSA strains in any health care setting. Concomitantly, regular
surveillance and effective infection control initiatives are desirable to reduce the incidence of health care
associated infections due to MRSA and also of mupirocin resistance.
Keywords: MRSA, Decolonization, Mupirocin, Resistance, Pakistan (JPMA 61:519; 2011).
differentiation of both types has important clinical
implications. The presence of high-level mupirocin resistance
(HLMR) excludes its clinical use, however low-level
mupirocin resistance (LLMR) can be overcome by
recommending higher than usual dosage.6
Resistance to mupirocin among clinical isolates of
MRSA has already been reported worldwide.7-9 Though
mupirocin has been available as an over the counter drug in
Pakistan, the extent of resistance in endemic MRSA isolates
is still unknown. Therefore this study was planned to assess
the level of mupirocin resistance through a cost effective and
convenient method which can be easily adapted by any
clinical microbiology laboratory. 
Materials and Methods
This study was conducted in the Clinical
Microbiology laboratory of the Aga Khan University
Hospital, Pakistan. The hospital and its laboratory are
accredited with the Joint commission of international
accreditation (JCIA). The laboratory routinely participates in
external quality control surveys with the College of American
pathologists (CAP). This Clinical microbiology laboratory
receives 400,000 specimens/year from both inpatients and
outpatients from clinics and hospitals within the city as well
as from all over the country via its laboratory collection
points in 50 major cities and towns of Pakistan. Hence the
laboratory data presented in this study represents strains
prevalent across the country.
Collection of clinical isolates: 
A total of 200 non duplicate clinical isolates of MRSA
were randomly selected and studied between January 2008
and June 2009. These were isolated from abscess, tracheal
aspirates, blood and urine. All specimens were processed in
the central laboratory based in Karachi. Identification and
sensitivity testing was done using standard microbiological
procedure using Clinical laboratory Standards Institute (CLSI)
guidelines.10 Resistance to methicillin was determined using a
30µg cefoxitin disc (Oxoid Limited, UK), on Mueller-hinton
agar according to current CLSI guideline. Staphylococcus
aureus ATCC strain 33591 was used as the control. 
Testing of susceptibility to mupirocin:
This was done by the disk diffusion method using 5µg
and 200µg mupirocin discs (Oxoid Limited, UK) to
determine low and high level resistance respectively. Criteria
of zone diameter breakpoints for susceptible and resistant
isolates were set at > 14mm and < 13mm respectively, as
recommended by Finlay et al.11 Antimicrobial resistance to
11 other antibiotics, amikacin (30µg), chloramphenicol
(30µg), gentamicin (30µg), clindamycin (2µg), erthyromycin
(15µg), fusidic acid (10), ofloxacin (5µg), trimethoprim-
sulfametoxazole (25µg), tetracycline (30µg), vancomycin
(30µg) and tegicycline (15µg) (Oxoid Limited, UK) was also
determined by the disc diffusion method.
The collected data was analyzed and evaluated on the
basis of averages and percentage values. The results were
presented in the form of tables. 
Results
Of the 200 strains of MRSA, 156 (78%) were isolated
from pus or abscesses, 40 (20%) from tracheal aspirates, 3
(1.5%) from blood, and 1 (0.5%) from urine as shown in
(Table). The overall frequency of low level and high level
resistance to mupirocin was 1% and 0% respectively. 
The 2 MRSA isolates that were found to be low level
mupirocin resistant were also found resistant to other
antibiotics compared to the mupirocin sensitive strains, with
sensitivities limited to chloramphenicol and vancomycin.
The proportion of the MRSA strains resistant to other
antibiotics was as follows: amikacin was 20%,
chloramphenicol 9%, gentamicin 78.5%, clindamycin 72%,
erthyromycin 84%, fusidic acid 15%, cefoxitin 100%,
ofloxacin 83.5%, penicillin 100%, co trimoxazole 56%,
tetracycline 72%, vancomycin 0% and tegicycline 0%. 
Discussion
In this study high level mupirocin resistance was not
found among clinical MRSA isolates and minimal number of
isolates showed low level resistance. These findings are
comparable to the resistance rates reported from
neighbouring countries but are lower than the rates reported
from other parts of the world.7-9,12
Since alternatives to mupirocin for eradicating MRSA
carriage are limited, it is important to have the knowledge of
prevalence of mupirocin resistance among MRSA as it will
facilitate effective decolonization. Therefore it is essential for
clinical laboratories not only to discriminate between
susceptible and resistant strains but also to determine the
level of resistance.
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Table: Site of infection and frequency of resistance to mupirocin
among 200 isolates of MRSA at the Aga Khan University Hospital.
No. of mupirocin-sensitive and resistant isolates
Site of Number (%) Sensitivity to LLR (5ug) HLR 
infection of Isolates mupirocin (%) (%) (20ug)
Blood 3 (1.5) 2 (66.6 ) 1 (33.3) 0
Pus/abscess 156 (78) 155 (99.3) 1 (0.64) 0
TA 40 (20) 40 (20) 0 0
Urine 1 (0.5) 1 (0.5) 0 0
Total 200 198 (99) 2 (1.0) 0
LLR= Low level mupirocin resistance
HLR= High level mupirocin resistance.
Keeping in view that the mupirocin resistant strains
were also found to be multidrug resistant, it would be
essential to eradicate these strains by decolonization rather
than treatment with the limited and expensive therapeutic
options available.
To the best of our knowledge this is the first report
from Pakistan on mupirocin resistance in MRSA isolates.
Detection of low frequency of mupirocin resistance in
endemic isolates does not advocate its indiscriminate and
widespread usage. Experience had shown that this leads to
emergence of resistance. To keep the resistance in check,
judicious usage will have to be implemented. This includes
targeted prophylaxis rather than general prophylaxis; only in
cases where isolate is sensitive to mupirocin. For this reason,
nasal eradication should only be recommended in patients
and health care workers under selective circumstances, such
as in MRSA outbreaks. Other valid uses are in high risk
patient population such as those with diabetes mellitus,
peripheral vascular disease, indwelling tubes, decubitus
ulcers or multi functional disabilities. 
In this study we used disc diffusion method for
detection of low and high level mupirocin resistance. The
"gold standard" method for detection of mupirocin resistance
is MIC determination by the agar dilution method. In
developed countries, molecular techniques also have been
utilized for the detection of the mupA gene. For a resource
limited country, molecular methods add to the burden of
growing costs of diagnosis and management. Additionally,
agar dilution method proves to be expensive and laborious for
routine application. This makes the disc diffusion
susceptibility test a cheaper and simple alternative method for
its routine use.
The sensitivity and specificity of this method has
already been evaluated by Malaviolle et al previously.13 They
found that 5µg mupirocin disc has a sensitivity of 100% and
a specificity of 98.1% whereas the 200µg mupirocin disk has
a sensitivity of 100% and specificity of 92.3% to differentiate
HLMR from LLMR. Malaviolle stated that the most accurate
disk diffusion test results were obtained with the 20µg
mupirocin disk test by using their proposed tentative
interpretative breakpoints or with the concomitant use of 5µg
mupirocin and 200µg mupirocin disks.13 Hence the disc
diffusion method could help in identifying low level
mupirocin strains in a fast feasible way. 
This literary proof and our study being the first report
of mupirocin resistance from the county are the biggest
strengths of our study. But the small sample size and lack of
a confirmatory test do prove to be definite weaknesses.
Studies with larger sample size will be required to explore the
prevalence mupirocin prevalence further.
Hence, the assessment of prevalence of mupirocin
resistance can be utilized as an important epidemiological
tool in institutions before the introduction of mupirocin
decolonization as a part of their infection control measures, as
well as an indicator to monitor mupirocin's judicious usage.
In conclusion, only low level resistance was found in
1% of MRSA. It is recommended as a primary drug for nasal
MRSA eradication.
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